Literature DB >> 10805319

Direct micro-radioimmunoassay of the new renin inhibitor CGP 60536.

G Lefévre1, M Duval, A Poncin.   

Abstract

A solid phase method for direct radioimmunoassay in plasma of the new renin inhibitor CGP 60536 has been developed which does not require the extraction of the parent drug with organic solvents. The assay showed a good reproducibility down to plasma concentrations of 0.15 ng/ml (LOQ) with intra- and inter-assay coefficients of variation < or = 20%. The procedure, which requires only small volumes of plasma (25 microl), is simple to use and well suited for routine analysis. The method allows the investigation of the pharmacokinetics of CGP 60536 in animals and man given low oral doses of the drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805319     DOI: 10.1080/01971520009349500

Source DB:  PubMed          Journal:  J Immunoassay        ISSN: 0197-1522


  3 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of aliskiren.

Authors:  Sujata Vaidyanathan; Venkateswar Jarugula; Hans Armin Dieterich; Dan Howard; William P Dole
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

2.  Spectrofluorimetric determination of aliskiren in tablets and spiked human plasma through derivatization with dansyl chloride.

Authors:  Zeynep Aydoğmuş; Ferhat Sarı; Sevgi Tatar Ulu
Journal:  J Fluoresc       Date:  2011-09-29       Impact factor: 2.217

3.  Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension.

Authors:  Iwona Zaporowska-Stachowiak; Karolina Hoffmann; Wiesław Bryl; Andrzej Minczykowski
Journal:  Arch Med Sci       Date:  2013-04-30       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.